John Clapham

John Clapham is Founder and CEO of PSC Biotech Corporation, PSC Software, and BioTechnique, and CEO of Future Cures. With over 30 years of experience in life sciences, pharmaceutical, and biotechnology industries, he has built a global portfolio focused on compliance, manufacturing excellence, and scientific innovation. John holds a B.S. in Chemical Engineering from the University of Rhode Island and began his career with organizations including the U.S. Department of Defense, Johnson & Johnson, and Fluor Daniel. A certified Computerized System Auditor (PDA) and certified Regulatory Affairs Professional (RAPS), John is a past two-term President of the ISPE Greater Los Angeles Chapter, current VP of Programs for the ISPE Delaware Valley Chapter, active member of the ISPE AI Community of Practice, and Executive Steering Committee member for the BioMap Consortium for Drug Product. His organizations span multinational consulting, enterprise SaaS platforms (including ACE and AuditUtopia), aseptic fill-finish contract manufacturing through BioTechnique in York, Pennsylvania, and Future Cures, a 501(c)(3) non-profit funding research into diseases lacking effective treatments.